Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

Go back to Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
(NASDAQ: XGN) Delayed: 13.54 +0.99 (7.89%)
Previous Close $12.55    52 Week High $0.46 
Open $12.54    52 Week Low $0.46 
Day High $14.03    P/E N/A 
Day Low $12.51    EPS $0.00 
Volume 43,269